Summit Therapeutics (SMMT) Insider Trades, Congress & Funds

Smart money at a glance

Filings to Nov 13, 2026

No insider open-market trades in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.

Company insidersForm 4, 90 days: $0
CongressSTOCK Act, 180 days: None
Big funds13F, quarter ended Jun 30, 2026: 4 added, 0 cut
Federal contractsUSAspending.gov, 12 months: No awards

Analysts

What do analysts expect?

Analyst target and ratings are on paid plans

Unlock the full results

Questions about SMMT filings

Are insiders buying or selling Summit Therapeutics PLC (SMMT) stock?

Neither. Summit Therapeutics PLC (SMMT) insiders filed no open-market purchases or sales in the 90 days to Nov 13, 2026, according to SEC Form 4 filings.

Which members of Congress have traded SMMT recently?

None. No member of Congress disclosed a SMMT trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.

How current is this SMMT smart-money data?

This summary uses filings available on Nov 13, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.

13F: filed up to 45 days late.

Smart money on SMMT

Lean long2 sources:
- Insiders
- Funds

Top traders
No tracked positions at the last update
Insiders
Lean long3 buys · $101M
Form 4 filings, open market.
Congress
No recent politician filings found
Funds
Lean long3 added · 0 trimmed
Quarter-end 13F holdings changes, not live trades. A trim is not a short.
Influencers
No recent posts found

Each bar is 100% of that source’s money. The notch marks an even split.

Lean is the direction of the latest moves. Descriptive, not advice.

Questions about SMMT filings

Are insiders buying or selling Summit Therapeutics PLC (SMMT) stock?

Neither. Summit Therapeutics PLC (SMMT) insiders filed no open-market purchases or sales in the 90 days to Nov 13, 2026, according to SEC Form 4 filings.

Which members of Congress have traded SMMT recently?

None. No member of Congress disclosed a SMMT trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.

How current is this SMMT smart-money data?

Funds

What funds are doing

4 moves · 6 mo

Buys/Adds$105.0M

Buys/Adds (3)

P7
Point72
Steven Cohen · Q2 2026 13F
$39.0M
added
Signals like this: n=13773, 53% finished lower at D15, median -0.4% vs SPY -0.4%
MI
Millennium
Israel Englander · Q2 2026 13F
$31.8M
added
BA
Balyasny
Dmitry Balyasny · Q2 2026 13F
$17.3M
added

1 more moves

Pro opens all of them for $16.50/month, paid yearly.

Unlock all 1 moves

Other smart money signals

Activist stakes, short interest & more

3 items

SI
Short Interest ChangeModerate
short-volume tape softening: latest 41.9% fell 19.0pp vs 20d avg 60.9%
SI
Short Interest ChangeModerate
short-volume tape softening: latest 41.9% fell 19.0pp vs 20d avg 60.9%
SI
Short Interest ChangeLight
short-volume tape softening: latest 50.1% fell 9.6pp vs 20d avg 59.7%

Unlock everything for $29/month

Unlock for $29/month

Reported Nov 4, 2026

Earnings came in 7.2% above what analysts expected.

Documents

Quarterly report10-Q Annual report10-K Every filing

Last report

Nov 4, 2026

Period ending

Sep 30, 2026

Earnings per share

-$0.19+7.24% beat

-$0.21 expected

Revenue

GBP 0.00

Financial statements: Alpha Vantage

EPS: Yahoo Finance

Next report

What the street expects next

Estimates as of Nov 13, 2026

EPS expected

-$0.22

-$0.28 to -$0.17

Revenue expected

$1.9M

11 analysts

Last 30 days

4up4down

Split both ways

Estimate drift

+0.03

Change in 30 days

Previous reports

Quarter / reported	Earnings per share	Beat or miss	Revenue / income	Revenue vs last year
Sep 30, 2026Reported Nov 4, 2026	-$0.19est. -$0.21	+7.24%beat	GBP 0.00Alpha Vantage	No year-ago quarter
Jun 30, 2026Reported Jul 23, 2026	-$0.21est. -$0.21	+2.05%beat	GBP 0.00Alpha Vantage	No year-ago quarter
Mar 31, 2026Reported Apr 30, 2026	-$0.18est. -$0.21	+14.25%beat	GBP 0.00Alpha Vantage	No year-ago quarter
Dec 31, 2025Reported Feb 23, 2026	-$0.21est. -$0.01	-$0.20miss	GBP 0.00Alpha Vantage	No year-ago quarter
Sep 30, 2025Reported Oct 20, 2025	-$0.23est. -$0.04	-$0.19miss	$0.00Alpha Vantage	No year-ago quarter
Jun 30, 2025Reported Aug 11, 2025	-$0.12est. -$0.09	-$0.03miss	GBP 0.00Alpha Vantage	No year-ago quarter
Mar 31, 2025Reported May 1, 2025	-$0.07est. -$0.07	+$0.00in line	GBP 0.00Alpha Vantage	No year-ago quarter
Dec 31, 2024Reported Feb 24, 2025	-$0.06est. -$0.06	+$0.00in line	GBP 0.00Alpha Vantage	No year-ago quarter

Earnings per share comes from Yahoo Finance where available, then Alpha Vantage or the company release. Revenue comes from company releases, SEC filings, Alpha Vantage or Yahoo Finance. A beat or miss needs an analyst estimate on the same basis as the reported figure, so quarters without one show none. Non-USD amounts carry their currency code.

Open: $17.90
High: $17.94
Low: $16.59
Prev close: $17.83
52-wk high: $29.23
52-wk low: $12.07
Mkt cap: $11.55B
ROE: -220.0%
Fwd P/E: 3.7x
Beta: -1.52
P/S: 3891.3x
P/B: 23.6x
Profit margin: +0.0%
Op margin: +0.0%

Sep 2025 to Sep 2025

What it sold, what it cost, what was left.

RevenueProfit

Sep 2025

Income statement, 1 periods, all values in US dollars
USD	Sep 2025
What came in
RevenueTotal revenue	$0
What it spent
Research and development	$131.1M
Sales and adminSelling, general and administrative	$103.1M
Total operating expenses	$234.2M
What was left
Operating profitOperating income	-$234.2M
Interest on debtInterest expense	$0
Profit before tax	-$231.8M
Net profitNet income	-$231.8M
EBITDAEarnings before interest, tax, depreciation, amortisation	-$234.2M

Technicals

Price structure

This stock is in a strong uptrend.

Trend

Strong uptrend

100 / 100

RSI 14

54balanced

20D volatility

101%annualized

52-week range

$16.64

$12.07$29.23

20D support

$14.17recent floor

20D resistance

$18.15recent ceiling

Returns

5D +2.9%20D +10.0%60D +29.8%

Price vs moving averages

SMA20 +5.3%SMA50 +1.1%SMA200 +3.0%

Volume pace

0.65xvs prior 20D

Quarter / reported

Earnings per share

Beat or miss

Revenue / income

Revenue vs last year

Sep 30, 2026Nov 4, 2026

-$0.19est. -$0.21

+7.24%

GBP 0.00Alpha Vantage

No year-ago quarter

Jun 30, 2026Jul 23, 2026

-$0.21est. -$0.21

+2.05%

GBP 0.00Alpha Vantage

No year-ago quarter

Mar 31, 2026Apr 30, 2026

-$0.18est. -$0.21

+14.25%

GBP 0.00Alpha Vantage

No year-ago quarter

Dec 31, 2025Feb 23, 2026

-$0.21est. -$0.01

-$0.20

GBP 0.00Alpha Vantage

No year-ago quarter

Sep 30, 2025Oct 20, 2025

-$0.23est. -$0.04

-$0.19

$0.00Alpha Vantage

No year-ago quarter

Jun 30, 2025Aug 11, 2025

-$0.12est. -$0.09

-$0.03

GBP 0.00Alpha Vantage

No year-ago quarter

Mar 31, 2025May 1, 2025

-$0.07est. -$0.07

+$0.00

GBP 0.00Alpha Vantage

No year-ago quarter

Dec 31, 2024Feb 24, 2025

-$0.06est. -$0.06

+$0.00

GBP 0.00Alpha Vantage

No year-ago quarter

Income statement, 1 periods, all values in US dollars
USD	Sep 2025
What came in
RevenueTotal revenue	$0
What it spent
Research and development	$131.1M
Sales and adminSelling, general and administrative	$103.1M
Total operating expenses	$234.2M
What was left
Operating profitOperating income	-$234.2M
Interest on debtInterest expense	$0
Profit before tax	-$231.8M
Net profitNet income	-$231.8M
EBITDAEarnings before interest, tax, depreciation, amortisation	-$234.2M

USD

Sep 2025

What came in

RevenueTotal revenue

What it spent

Research and development

$131.1M

Sales and adminSelling, general and administrative

$103.1M

Total operating expenses

$234.2M

What was left

Operating profitOperating income

-$234.2M

Interest on debtInterest expense

Profit before tax

-$231.8M

Net profitNet income

-$231.8M

EBITDAEarnings before interest, tax, depreciation, amortisation

-$234.2M

Summit Therapeutics PLC

Smart money at a glance

What do analysts expect?

Questions about SMMT filings

Smart money on SMMT

Questions about SMMT filings

What funds are doing

What insiders are doing

How top traders are positioned

Activist stakes, short interest & more

Unlock everything for $29/month

Earnings came in 7.2% above what analysts expected.

What the street expects next

Previous reports

What it sold, what it cost, what was left.

Price structure

Ask it in Claude or ChatGPT.

Summit Therapeutics PLC

Smart money at a glance

What do analysts expect?

Questions about SMMT filings

Smart money on SMMT

Questions about SMMT filings

What funds are doing

What insiders are doing

How top traders are positioned

Activist stakes, short interest & more

Unlock everything for $29/month

Earnings came in 7.2% above what analysts expected.

What the street expects next

Previous reports

What it sold, what it cost, what was left.

Price structure

Ask it in Claude or ChatGPT.

Summit Therapeutics PLC

Overview

Questions about SMMT filings

Smart money

Unlock everything for $29/month

Earnings

Previous reports

Financials

Technicals

Ask it in Claude or ChatGPT.

Summit Therapeutics PLC

Overview

Questions about SMMT filings

Smart money

Unlock everything for $29/month

Earnings

Previous reports

Financials

Technicals

Ask it in Claude or ChatGPT.